We show that an Aβ-targeting antibody remarkably amplified microglial synapse pruning both in neuron-microglia cocultures and in APP/PS1 mice via the complement-dependent pathway, resulting in significant synapse loss and cognitive deficits in APP/PS1 mice, which may reveal the possibility of the clinical trial failure of AD immunotherapy. This evidence concerns the gene APP and Alzheimer disease.